Health Canada has new API guidelines; New Xcelience plant aims for EU market;

> A report says Medicare has the ability to cut off payments for drugs made by compounders under large manufacturing conditions but it is unclear how often it does so. Story

> Health Canada has published new draft guidelines for GMP of active pharmaceutical ingredients and is seeking responses. Release

> Israel-based BiondVax Pharmaceuticals says its manufacturing plant has passed an EU GMP inspection. Release

> Xcelience has opened a new plant in Tampa, FL, and it intends to make clinical trial supplies for markets outside the U.S. there. Story

And Finally... Indian drug manufacturer Aurobindo has told investors that it has upgraded a cephalosporin plant that the FDA placed under an import alert earlier this year and expects it to be approved to again ship APIs to the U.S. by the end of the year. Story

Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.